

BAUSCH + LOMB

enVista Envy™

Full Range of
Vision IOLs



enVista

Toric

Studies

Design

Lighting

Pt. Satisf'n

Dysphot.

enVista ENVY™

FLOURISH
AT EVERY STEP



Discover the **FULL RANGE OF VISION IOL** that launches
a **new era of confidence** with **enviable outcomes**¹

FULL RANGE OF VISION CORRECTION

ACCESSIBLE TO ALL CATARACT SURGEONS¹

OUTSTANDING PERFORMANCE IN ALL LIGHTING CONDITIONS

WITH ACTIVSYNC - INTELLIGENT
ENERGY DISTRIBUTION⁴

TREAT ASTIGMATIC PATIENTS WITH MORE PRECISION^{* 5}

EXCELLENT PATIENT TOLERANCE

TO GLARE, HALOS, AND STARBURSTS^{2,3}

* Compared to range of cylinders offered with Alcon PanOptix CNWTT2-CNWTT6 and
Tecnis PureSee DET100-DET600, as listed on the Prescribed List in November 2024

Dysphot.

Pt. Satisf'n

Lighting

Design

Studies

Toric

enVista

**A full range of
vision comes with
high expectations**

enVista
HYDROPHOBIC ACRYLIC IOL
ENVY™

Dysphot.

Pt. Satisf'n

Lighting

Design

Studies

Toric

enVista

A lens with an enviable tolerance to dysphotopsia^{1, 2, 3*}

	enVista Envy ^{1, 2*}			
Types of dysphotopsia	% of patients with little to no bothersomeness		% of patients with severe disturbance	
Country	US (n=309 - 311)	Canada (n=110)	US (n=309 - 311)	Canada (n=110)
Glare	88%	96%	3%	0%
Halos	80%	88%	6%	6%
Starbursts	91%	94%	3%	1%

	PanOptix (n=127) ^{3*}	
Type of dysphotopsia	% of patients with little to no bothersomeness	% of patients with severe disturbance
Glare	73%	3%
Halos	73%	13%
Starbursts	72%	16%


*Respective patient reported outcome data at 4–6 months post-op (non-head-to-head) from enVista Envy US clinical study (n=309 - 311), 4–6 months post-op enVista Envy Canadian clinical study (n=110) and 6-month post-op AcrySof PanOptix clinical study (n=127)

enVista Envy can enhance your patients' visual experience in their daily-life activities²



91%

LITTLE TO NO DIFFICULTY
READING MOBILE SCREEN²



94%

LITTLE TO NO DIFFICULTY
VIEWING CLOSE OBJECTS²



95%

LITTLE TO NO DIFFICULTY
READING COMPUTER SCREEN²

enVista
HYDROPHOBIC ACRYLIC IOL
ENVY

Canadian Clinical Study, enVista Envy n=110 patient reported outcomes 4-6-month post-op, bilateral implantation

Dysphot.

Pt. Satisf'n

Lighting

Design

Studies

Toric

enVista

93%
of patients were
completely to
moderately
satisfied with
their vision²

enVista Envy Canadian Clinical Study, n=110 patient reported
outcomes 4–6-month post-op, bilateral implantation



Dysphot.

Pt. Satisf'n

Lighting

Design


Studies

Toric

enVista

ActivSync optic delivers intelligent energy distribution

enVista
HYDROPHOBIC ACRYLIC GEL
ENVY



Dysphot.

Pt. Satisfn

Lighting

Design


Studies

Toric

enVista



The ActiveSync optic in enVista Envoy is designed to **enhance image contrast** when patients need it most, evenly distributing light in photopic conditions and prioritizing distance in mesopic conditions.




Based on bench testing

enVista Envy demonstrated excellent performance


In **photopic conditions**, ActivSync optic maintained excellent full range of vision for patients.^{1,4}

enVista Envy defocus curve 3–4mm pupil size¹



...in all lighting conditions

In pupils larger than 4mm, ActivSync optic is able to prioritize light energy, which facilitates night vision.^{1,4}



enVista Envy US Clinical Study, binocular implantation, 4-6-month post-op, n=36 eyes

Intelligent optic design meets exceptional engineering

- Full range of vision diffractive anterior surface
- 1.2mm central zone
- 1.6 D intermediate and 3.1 D near adds
- Consistent $-0.15\mu\text{m}$ SA profile across full diopter range

enVista[®]
HYDROPHOBIC ACRYLIC IOL
ENVY[™]




12.5mm
lens length

6mm optic
diameter

SA = spherical aberration

In addition to **ActivSync optic**, enVista Envoy is enhanced with proprietary technology designed to reduce light scattering.²¹



**enVista Envy
demonstrated
exceptional
visual outcomes**

enVista
HYDROPHOBIC ACRYLIC IOL
ENVY



enVista Envy US Clinical Study

Dysphot.

Pt. Satisf'n

Lighting

Design

Studies

Toric

enVista

enVista Envy performance is supported by a robust US clinical study

A multicenter, randomized, and controlled clinical trial which assessed the safety and effectiveness of the enVista Envy IOL included a one-year follow-up period and demonstrated excellent long-term outcomes.¹



332 EN VISTA ENVY
(EST G D U P)

664 number of eyes

169 ENVISTA
(CONTROL GROUP)

338 number of eyes


23 INVESTIGATION
SITES

enVista Envy US Clinical Study

**enVista Envy™ delivers
excellent image contrast
for low-light visual clarity^{1,4}**

enVista
HYDROPHOBIC ACRYLIC IOL
ENVY™

Help your patients achieve spectacle independence¹



*enVista Envoy US Clinical Study, n=53 patients reported outcomes 4–6-month post-op, bilateral

enVista Envy achieved excellent mean visual acuity results in a robust US clinical study¹

Near



DCNVA Bilateral
Photopic Conditions
n=284
Achieved by 79%
of test subjects

Intermediate



DCIVA Bilateral
Photopic Conditions
n=283
Achieved by 91% of
test subjects

Distance



BCDVA Bilateral
Photopic Conditions
n=312
Achieved by 85% of
test subjects

enVista
HYDROPHOBIC ACRYLIC IOL
ENVY™

enVista Envy US Clinical Study, bilateral implantation, 4-6-month post-op

Dysphot.

Pt. Satisf'n

Lighting

Design

Studies

Toric

enVista



Dysphot.

Pt. Satisfn

Lighting

Design

Studies

Toric

enVista


Low-Cyl technology expands options for low astigmatism treatment

With Low-Cyl technology:

Broaden the treatable astigmatism range in cataract surgery to as low as 0.9 D at the IOL plane.¹⁰

The first and only full range of vision toric platform available

providing Low-Cyl toric technology (0.9 D at the IOL plane)




of cataract patients have less than 1.25 D of corneal astigmatism.¹¹

Astigmatism treatment options for patients with MORE precision*

- **Lowest** available cylinder treatment: 0.9 D at IOL plane⁵
- **Maximum** available cylinder treatment: 5.75 D at IOL plane⁵
- **Only** toric platform that treats half-step cylinders (up to 3.5 D at IOL plane)⁵


Astigmatism treatment (IOL plane)




* Compared to range of cylinders offered with Alcon PanOptix CNWTT2-CNWTT6 and Tecnis PureSee DET100-DET600, as listed on the Prescribed List in November 2024

The enVista platform is tailored for EXCELLENT stability and toric outcomes

Toric alignment and rotational stability are vital for patient satisfaction and visual outcomes.




110° of capsular bag contact




enVista platform⁴

88° of capsular bag contact



AcrySof IQ/CLAREON platform⁴

84° of capsular bag contact





TECNIS platform⁴

Achieve reliable rotational stability for precise astigmatism correction

- 110° of capsular bag contact
- Delivers 300% more radial compression force than traditional hydrophobic IOLs¹⁶
- Demonstrated higher outward radial force compared to the TECNIS IOL platform¹⁶

Radial compression force - IOL platforms¹⁷





The enVista toric platform delivers proven rotational stability through **180 days post-surgery**²⁷

Percent of eyes $\leq 5^\circ$ rotation ($n=108$)

enVista
HYDROPHOBIC ACRYLIC LID
ENVY TORIC

Dysphot.

Pt. Satisf'n

Lighting

Design

Studies


Toric

enVista

Simplified intraoperative lens manipulation

The unique fenestration holes of enVista Envy Toric simplify lens manipulation during surgery,²⁶ allowing **both clockwise and counterclockwise** positioning in the capsular bag.

The fenestrated haptics also reduce haptic-to-optic stress, ensuring lens integrity during capsular bag contraction.



The enVista Toric Calculator

Your partner in accuracy

Powered by the advanced Emmetropia Verifying Optical (EVO) formula, the enVista Toric Calculator sets the new standard for predicting spherical equivalence and providing data for low astigmatism cases.¹⁸

The EVO formula includes posterior corneal astigmatism (PCA) modeling and IOL geometry considerations¹ to determine spherical equivalent refractive error, and the suitable IOL power, based on biometry.

enVista
HYDROPHOBIC ACRYLIC IOL
ENVY TORIC

Using the EVO formula:

- Around 80% of patients achieve a targeted range of 0 to 0.5 D, surpassing traditional vergence formulas.¹⁹
- The proportion of eyes with a refractive astigmatism of ≤ 1.0 D is statistically superior compared to the Kane formula.²⁵
- Improved alignment between predicted and actual refractive astigmatism compared to legacy formulas.¹⁸



Scan to access the enVista Toric Calculator
<https://envista.toriccalculator.com/>

Delivery system

Available for enVista Envy and enVista Envy Toric IOLs



BLIS® (reusable solution)


- Quality engineering and built from high-grade titanium
- Requires a small incision size of 2.2mm to 2.4mm, for smooth lens deliveries²⁰

enVista

HYDROPHOBIC ACRYLIC IOL

ENVY™

EN order number ENUXXXX



X represents diopter

MODEL NUMBER	EN (non-preload)
MATERIAL	Hydrophobic Acrylic
OPTIC DESIGN	One-piece Aspheric, biconvex Anterior apodized diffractive Posterior refractive Posterior aspheric surface 1.6 D intermediate 3.1 D near
OPTIC SIZE	6mm
LENGTH	12.5mm
OPTIC EDGE DESIGN	Sharp 360° square posterior edge
HAPTICS	Modified C, fenestrated
REFRACTIVE INDEX	1.53 at 35° C
UV CUTOFF	389nm at 10% transmittance
OPTICAL BIOMETRY	
Barrett Universal II	a-constant 119.28, LF 2.03
EVO 20	a-constant 119.24
Hill-RBF 3.0	a-constant 119.26
SRK/T	a-constant 119.25
Hoffer Q	pACD: 5.788
Holladay I	SF: 1.981
OTHER FEATURES	Glistering free
DIOPTRER RANGE	+6 D to +10 D (1.0 D increments) +10 D to +34 D (0.5 D increments)

* A-constant values are suggested as a guideline. Physicians should calculate lens power based on optimization of their experience and preference with IOL technology.

Dysphot.

Pt. Satisf'n

Lighting

Design

Studies

Toric


enVista

enVista[®] TORIC

HYDROPHOBIC ACRYLIC IOL

ENVY[™]

ETN order number ETNU CCC+XXX



C represents cylinder, X represents diopter

MODEL NUMBER	ETN (non-preload)
MATERIAL	Hydrophobic Acrylic
OPTIC DESIGN	One-piece Aspheric, biconvex Anterior apodized diffractive Posterior refractive Posterior toricity 1.6 D intermediate 3.1 D near
OPTIC SIZE	6mm
LENGTH	12.5mm
OPTIC EDGE DESIGN	Sharp 360° square posterior edge
HAPTICS	Modified C, fenestrated
REFRACTIVE INDEX	1.53 at 35° C
UV CUTOFF	389nm at 10% transmittance
OPTICAL BIOMETRY	
Barrett Universal II	a-constant 119.28, LF 2.03
EVO 20	a-constant 119.24
Hill-RBF 3.0	a-constant 119.26
SRK/T	a-constant 119.25
Hoffer Q	pACD: 5.788
Holladay I	SF: 1.981
OTHER FEATURES	Glistering free
DIOPTRER RANGE	+6 D to +34 D (0.5 D increments)
CYLINDER POWERS IOL PLANE	0.9, 1.25, 1.50, 2.00, 2.50, 3.00, 3.50 D

* A-constant values are suggested as a guideline. Physicians should calculate lens power based on optimization of their experience and preference with IOL technology.

Dysphot.

Pt. Satisf'n

Lighting

Design

Studies

Toric

enVista

Advanced enVista IOL platform features

TruSight® technology

Glistening-free material* with improved scratch resistance and 25x the hardness of traditional hydrophobic acrylic IOLs.^{22,**}

StableFlex® technology

Efficient lens unfolding, ensuring excellent optic recovery.¹²

SureEdge® design

Outstanding defense against Posterior Capsular Opacification (PCO).^{12, 24}



*Glistenings are observed by ophthalmologists at the slit lamp as backscatter. There has been no established correlation between these backscatter observations and what patients observe.

**Based on nanoindentation study

References

1. Data on File. enVista Envy US Clinical Study, conducted with model MX60EF
2. Data on File. enVista Envy Canadian Clinical Study, conducted with model MX60EFH
3. Alcon AcrySof PanOptix Clinical Study.
4. Data on File, Bausch+Lomb.
5. enVista Envy Toric Directions for Use, Bausch & Lomb.
6. Hayashi K, Yoshida M, Igarashi C, Hirata A. Effect of Refractive Astigmatism on All-Distance Acuity in Eyes with a Trifocal Intraocular Lens. *American J Ophthalmol.* 2021;221: 279-286. doi: 10.1016/j.ajo.2020.07.051.
7. Residual Astigmatism on Visual Outcomes After Trifocal Intraocular Lens Zhang L, Shen W, Shen J, Wang M, Ni S, Guo H, Yang J. Effect of Postoperative Implantation. *Front Med.* 2023; 10:1202793 doi: 10.3389/fmed.2023.1202793.
8. Lake JC, Victor G, Clare G, et al. Toric intraocular lens versus limbal relaxing incisions for corneal astigmatism after phacoemulsification. *Cochrane Database Syst Rev.* 2019;12(12):CD012801. doi: 10.1002/14651858. CD012801. pub2.
9. Sci. 1997;74(7):521-526. Novis C. Astigmatism and Toric Intraocular Lenses. CMuilerernAtDO, pKirmisioMnJ,inGORifpfihtthsaAlmC.oEllofgeyct2o0f0s0m; VaoIII fo1c1a, llsesruoer1s:o4n7-v5is0io. n. *Optom Vis*
10. enVista Toric Directions for Use, Bausch & Lomb.
11. Holland EJ. Treating Astigmatism With Torics. In: *Cataract & Refractive Surgery Today Supplement.* 2010 Feb. p. 5-6. Available from: https://crstoday.com/wp-content/themes/crst/assets/downloads/0210_supp.pdf
12. enVista Envy Directions for Use, Bausch & Lomb.
13. Clareon PanOptix Directions for Use, Alcon.
14. TECNIS PureSee Specifications PP2023CT5543, Johnson & Johnson.
15. Roach L. Toric IOLs: Four Options for Addressing Residual Astigmatism. *Clinical Update in EYENET*, April 2012, 29 - 31.
16. Bozukova D, Pagnouille C, Jérôme C. Biomechanical and optical properties of 2 new hydrophobic platforms for intraocular lenses. *J Cataract Refract Surg.* 2013;39(9):1404-1414.
17. Pilon, A et al. ARVO Annual Meeting Abstract 60(9) 2019. <https://iovs.arvojournals.org/article.aspx?articleid=2745799> . Accessed 17-Feb-2025. Sponsored by Bausch & Lomb
18. Pantanelli SM, Kansara N, Smits G. Predictability of residual postoperative astigmatism after implantation of a toric intraocular lens using two different calculators. *Clin Ophthalmol.* 2020;14:3627–3634. doi: 10.2147/OPTH.S276285.
19. Melles RB, Kane JX, Olsen T, Chang WJ. Update on intraocular lens calculation formulas. *Ophthalmol.* 2019;126(9):1334-1335.
20. Data on file. Blis Insertter.
21. Data on File, Bausch + Lomb
22. Heiner P, Ligabue E, Fan A and Lam D. Safety and effectiveness of a single- piece hydrophobic acrylic intraocular lens (enVista®) – results of a European and Asian-Pacific study. *Clinical Ophthalmology* 2014;8 629-635
23. N/A
24. Pai HV, Pathan A, Kamath YS. A comparison of posterior capsular opacification after implantation of three different hydrophobic square edge intraocular lenses. *Indian J Ophthalmol.* 2019;67(9):1424-1427. doi: 10.4103/ijo.IJO_219_19.
25. Bordewyk AN, et al. Cataract surgery refractive outcomes in long eyes: a comparison of 7 formulas. *The Association for Research in Vision and Ophthalmology Annual Meeting*; May 1-7, 2021; Virtual.
26. Wiley WF. Rotational stability of aberration neutral hydrophobic toric IOL with enhanced delivery characteristics. Presented at: ASCRS Annual Meeting; April 22-26, 2022; Washington, D.C.
27. Data on File. enVista Toric MX60ET US Clinical Study

For more information about
enVista Envy™ & enVista Envy™ Toric
please visit **bauschsurgical.com***



* International website

© 2024 Bausch & Lomb Incorporated. ®/TM denote trademarks of Bausch & Lomb Incorporated and its affiliates.

Other product names/ brand names are trademarks of their respective owners.

Bausch & Lomb (Australia) Pty Ltd. ABN 88 000 222 408. Level 2, 12 Help Street, Chatswood NSW 2067 Australia. (Ph 1800 251 150)

New Zealand Distributor: Toomac Ophthalmic. 32D Poland Road, Glenfield 0627 Auckland New Zealand (Ph 0508 443 5347)

EVE.0001.AU.24

BAUSCH + LOMB

Dysphot.

Pt. Satisf'n

Lighting

Design

Studies

Toric

enVista